Tumor progression in non-small cell lung cancer (NSCLC) was associated with PPARβ/δ upregulation, an increase in VEGF (vascular endothelial growth factor) levels and activation of the PI3K/Akt pathway [178]. This evidence concerns the gene VEGFA and neoplasm.